Bristol-Myers Squibb Co reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, but sparked concerns over a possible delay in completing its marketing application for a high-profile cancer drug.Shares of the U.S. drugmaker, whose sales missed Wall Street estimates, were down 3.6 percent at $48.54 in afternoon trading on Tuesday.Bristol-Myers said it had earned $937 million, or 56 cents per share, in the first quarter, compared with $609 million, or 37 cents per share, a year earlier.Excluding gains from the recent sale of its diabetes drug business to longtime partner AstraZeneca Plc and other special items, Bristol-Myers earned 46 cents per share. Analysts on average were expecting 43 cents, according to Thomson Reuters I/B/E/S.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. Shares of AZN traded higher by 0.69% or $0.53/share to $77.54. In the past year, the shares have traded as low as $46.87 and as high as $79.90. On average, 2822850 shares of AZN exchange hands on a given day and today's volume is recorded at 7866318.
Thomson Reuters Corporation (Thomson Reuters), is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 1.24% or $0.43/share to $35.08. In the past year, the shares have traded as low as $31.38 and as high as $38.73. On average, 836660 shares of TRI exchange hands on a given day and today's volume is recorded at 557980.
Thomson Reuters Corporation (Thomson Reuters), is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 0.58% or $0.22/share to $38.43. In the past year, the shares have traded as low as $33.02 and as high as $42.10. On average, 964052 shares of TRI.TO exchange hands on a given day and today's volume is recorded at 250011.
Source
